CR9032A - Fumarato de 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino-2- pirimidinil)amino)benzonitrilo - Google Patents

Fumarato de 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino-2- pirimidinil)amino)benzonitrilo

Info

Publication number
CR9032A
CR9032A CR9032A CR9032A CR9032A CR 9032 A CR9032 A CR 9032A CR 9032 A CR9032 A CR 9032A CR 9032 A CR9032 A CR 9032A CR 9032 A CR9032 A CR 9032A
Authority
CR
Costa Rica
Prior art keywords
amino
dimethylphenyl
pyrimidinyl
cyanethethyl
benzonitrile fumarate
Prior art date
Application number
CR9032A
Other languages
English (en)
Inventor
Theodoor Agnes Stevens Paul
Peeters Jozef
Petrus Gerebern Vandecruys Roger
Elisabeth Stappers Alfred
Herman Copmans Alex
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from MYPI20043578A external-priority patent/MY169670A/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR9032A publication Critical patent/CR9032A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se relaciona con la sal fumarato de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo, composiciones farmaceuticas que comprenden como ingrediente activo a la sal y con procedimientos para su preparacion.
CR9032A 2004-09-02 2007-03-30 Fumarato de 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino-2- pirimidinil)amino)benzonitrilo CR9032A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MYPI20043578A MY169670A (en) 2003-09-03 2004-09-02 Combinations of a pyrimidine containing nnrti with rt inhibitors
PCT/EP2004/052028 WO2005021001A1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
EP05101447 2005-02-25

Publications (1)

Publication Number Publication Date
CR9032A true CR9032A (es) 2009-07-30

Family

ID=38091631

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9032A CR9032A (es) 2004-09-02 2007-03-30 Fumarato de 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino-2- pirimidinil)amino)benzonitrilo

Country Status (19)

Country Link
US (3) US20090215804A1 (es)
EP (1) EP1789139B1 (es)
JP (1) JP4922937B2 (es)
KR (1) KR101276571B1 (es)
AP (1) AP2487A (es)
AT (1) ATE550074T1 (es)
AU (1) AU2005279157B2 (es)
BR (1) BRPI0514861A (es)
CA (1) CA2577273C (es)
CR (1) CR9032A (es)
DK (1) DK1789139T3 (es)
EA (1) EA011036B1 (es)
ES (1) ES2384715T3 (es)
HR (1) HRP20120499T1 (es)
IL (1) IL181649A0 (es)
MX (1) MX2007002594A (es)
NI (1) NI200700069A (es)
NO (1) NO339788B1 (es)
SI (1) SI1789139T1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2702044B1 (en) 2011-04-25 2017-03-22 Hetero Research Foundation Process for rilpivirine
KR20220077143A (ko) * 2019-10-10 2022-06-08 악셀라 헬스 인크. 아미노산 엔티티를 포함하는 부피가 감소된 제형물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498419A (en) * 1994-06-03 1996-03-12 Pars; Harry G. Fumarate salt of 4-(diethyl-3-(1-methyloctyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol, 4-(diethyl-amino) butyric
EP0951278A2 (en) * 1997-01-03 1999-10-27 ELAN CORPORATION, Plc Sustained release cisapride mini-tablet formulation
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
DK1529032T3 (da) * 2002-08-09 2013-07-08 Janssen Pharmaceutica Nv Fremgangsmåder til fremstilling af 4-4-4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)aminobenzonitrill
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
BRPI0407329A (pt) * 2003-02-07 2006-01-10 Janssen Pharmaceutica Nv Derivados de pirimidina para a prevenção de infecção de hiv
EP1596838A2 (en) * 2003-02-11 2005-11-23 Torrent Pharmaceuticals Ltd Once a day orally administered pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent

Also Published As

Publication number Publication date
EA200700534A1 (ru) 2007-08-31
EP1789139B1 (en) 2012-03-21
HK1112862A1 (en) 2008-09-19
IL181649A0 (en) 2007-07-04
HRP20120499T1 (hr) 2012-07-31
AU2005279157B2 (en) 2011-07-14
AP2487A (en) 2012-10-03
KR20070053284A (ko) 2007-05-23
NO20071720L (no) 2007-04-02
NO339788B1 (no) 2017-01-30
ES2384715T3 (es) 2012-07-11
SI1789139T1 (sl) 2012-08-31
AU2005279157A1 (en) 2006-03-09
EA011036B1 (ru) 2008-12-30
JP2008511591A (ja) 2008-04-17
NI200700069A (es) 2015-12-10
JP4922937B2 (ja) 2012-04-25
US20180116964A1 (en) 2018-05-03
AP2007003933A0 (en) 2007-04-30
KR101276571B1 (ko) 2013-06-18
DK1789139T3 (da) 2012-07-09
US20090215804A1 (en) 2009-08-27
BRPI0514861A (pt) 2008-06-24
EP1789139A1 (en) 2007-05-30
MX2007002594A (es) 2007-04-25
CA2577273C (en) 2013-11-19
ATE550074T1 (de) 2012-04-15
CA2577273A1 (en) 2006-03-09
US20110150996A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
NI200700068A (es) Clorhidrato de 4-[[4-[[4-(2-cianoetenil)-2,6- dimetilfenil]amino]-2- pirimidinil]amino] benzonitrilo
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
AR023624A1 (es) Composiciones farmaceuticas que comprenden un inhibidor de hmg coa reductasa
BRPI0519474A2 (pt) derivados de quinazolina para inibir o crescimento de cÉlulas cancerosas e mÉtodo para a preparaÇço destes
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
BRPI0814252B8 (pt) composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia
CR9032A (es) Fumarato de 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino-2- pirimidinil)amino)benzonitrilo
CO6290762A2 (es) Nuevos derivados quinazolin-2, 4-diona y una composicion farmaceutica para prevenir a tratar la enfermedad neurocerebral
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
MX2009005329A (es) Composiciones farmaceuticas anticonvulsivas.
UA92469C2 (en) Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
ECSP088088A (es) Maleato de 3-[2-(dimetilamino)metil-(ciclohex-1-il)]fenol y sus formas cristalinas
UY30864A1 (es) Solucion coloidal
PA8626601A1 (es) Formas de dosificacion y composiciones farmaceuticas
CR9323A (es) TIAZOLIDINONAS COMO INHIBIDORAS DE LAS POLOQUINASAS (Plk) COMO MEDICAMENTO
HRP20110563T1 (en) Salt of 4[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
UY26840A1 (es) Composición farmacéutica a base de cocaetileno y su utilización para el tratamiento de la dependencia a las sustancias psicoactivas
CR7288A (es) Composiciones de disgregacion intraoral organolepticamente aceptables

Legal Events

Date Code Title Description
FC Refusal